GSK plc announced that its drug, GSK'227, received Orphan Drug Designation in the EU for treating small-cell lung cancer based on promising trial results from October 28, 2025. This designation highlights the drug's potential to help patients with limited treatment options, with around 250,000 diagnoses each year globally.